Shuang Pan
Boston
Summary
10 years of experience in anti-cancer drug development. Possess multiple skills in in vivo, in vitro, and analytical work. Experience in people management and excellent communication abilities.
Overview
10
10
years of professional experience
Work History
Research Scholar
University Of Houston & TractBio & Bach Bioscience
11.2022 - Current
- Lead project of the Multi-Kinase-Targeting SNIPERs (Specific non-genetic IAP-based protein erasers), drug conjugation as continuous work for Tufts.
- Responsible for screening the lead candidate that can kill stem cancer cells which are resistant to most other treatments and had obtained solid POC in mouse models
- Based on the above contribution, align with other remarkable work, Tract Bio pharma & Bach Bioscience recruit $1 billion funding in 2023.
Head of Bioanalytical & CMC Analytical Department
PharmaSolux
09.2021 - 12.2022
- Responsible for leading the roadshow efforts, conducting over 30 roadshows both on-site and remotely.
- Obtained licensing for SMDC & RDC from Tufts Patent, under Prof William Bachovchin's guidance.
Postdoctoral Researcher
Tufts University & Bach Bioscience
05.2019 - 11.2022
- Discovered a cocktail combination stabilizer, which can guarantee that the synthesis yield of boric acid-containing nuclear drugs at high temperature is above 95%, it is crutial step for PNT6555 which is in Phase I clinical trial.
- Identified the impurity, isomers and troubleshooting of FAP-targeted radiotheranostic agent for Preclinical development and IND enabling studies.
- Developed a dynamic assay method of FAP Cleavage compounds
- Collaborated with Point Biopharma & Avacta and got $10 million funding during 2020-2022, and two new chemical entities are in Phase Clinical I.
Assistant Professor
Jinzhou Medical University
09.2013 - 05.2019
- Demonstrate that MgCl2 and ZnCl2 enhanced the migration abilities of human umbilical vein endothelial cells (HUVECs), which is a potential therapeutic method to reduce the risks of in-stent restenosis by inhibiting HUVEC migration, invasion, EMT and angiogenesis
- Explored that miR-328-3p could be a promising therapeutic target for colorectal cancer, over expression inhibited colorectal cancer (CRC) cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT).
Head of Department for HighLevel Talent Management
Jinzhou Medical University
09.2014 - 06.2016
- Skilled at working independently and collaboratively in a team environment.
- Oversaw the management and coordination of talent acquisition and development initiatives for the university.
- Worked well in a team setting, providing support and guidance.
Education
Ph.D. - Biochemistry and Molecular Biology
China Medical University
B.E. - Clinical Medicine
China Medical University
Skills
- In vivo: Proficient in mouse modeling (tumor models), conducting PK/PD experiments, administering compounds via various routes (IP/IV/PO/SC), animal imaging;
- In vitro: Experienced in cell-based assays, assay development, PCR, Western blotting (WB), imaging techniques, flow cytometry, and enzymology-related work;
Timeline
Research Scholar
University Of Houston & TractBio & Bach Bioscience
11.2022 - Current
Head of Bioanalytical & CMC Analytical Department
PharmaSolux
09.2021 - 12.2022
Postdoctoral Researcher
Tufts University & Bach Bioscience
05.2019 - 11.2022
Head of Department for HighLevel Talent Management
Jinzhou Medical University
09.2014 - 06.2016
Assistant Professor
Jinzhou Medical University
09.2013 - 05.2019
Ph.D. - Biochemistry and Molecular Biology
China Medical University
B.E. - Clinical Medicine
China Medical University
Publications
MAIN JOURNAL PUBLICATIONS (Totally 16 publications, 237 citations)
1. Sarah E. Poplawski, Robin M. Hallett, Mark H. Dornan, Kyle E. Novakowski, Shuang Pan, Anthony P. Belanger, Quang-De Nguyen, Wengen Wu, Albert E. Felten, Yuxin Liu, Shin Hye Ahn, Valerie S. Hergott, Barry Jones, Jack H. Lai, Joe A.B. McCann, William W. Bachovchin. Preclinical development of PNT6555, a boronic acid-based, FAP-targeted radiotheranostic for imaging and treatment of FAP-positive tumors. J Nucl Med. 2023 (Received on Oct. 17, 2023)
2. Robin M. Hallett, Sarah E. Poplawski, Mark H. Dornan, Shin Hye Ahn, Shuang Pan, Wu Wengen, Liu Yuxin, David G. Sanford, Valerie S. Hergott, Quang-De Nguyen, Anthony P. Belanger, Jack H. Lai, William Bachovchin, Joe A. McCann. Pre-clinical characterization of the novel FAP targeting ligand PNT6555 for imaging and therapy of cancer. Cancer Research. 2022 82 (12_Supplement): 3303
2. A Vito, M Dornan, T Beale, A Felten, M Ernste, Q Nguyen, S Ahn, AP Belanger, S Pan, W Wu, Y Liu, JH Lai, WW Bachovchin, V Hergott, J McCann, R Hallett. Development and characterization of a next-generation Ac-225-PSMA radioligand. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2022 (49), S440-S440
Similar Profiles
Sebabatso KeeleSebabatso Keele
Student assistant at University of the Western Cape, Medical Bioscience departmentStudent assistant at University of the Western Cape, Medical Bioscience department
Bowen XuBowen Xu
Product Owner at School of BioScience, The University of MelbourneProduct Owner at School of BioScience, The University of Melbourne
Menaka GarapatyMenaka Garapaty
Research Intern at K-State University Olathe Bioscience LabsResearch Intern at K-State University Olathe Bioscience Labs
Indrajeet Aditya RoyIndrajeet Aditya Roy
Software Engineer Intern at AmwellSoftware Engineer Intern at Amwell
Katrina PortleyKatrina Portley
Professional Dog Bather at A Hair Of The DogProfessional Dog Bather at A Hair Of The Dog